B8.7 antigen is present on B-cell precursor acute lymphocytic leukemia. Correlation with the low molecular weight B-cell growth factor responsiveness of these cells. 1990

C Leprince, and N Blumenfeld, and G Flandrin, and P Galanaud, and F Sigaux, and Y Richard
Inserm U 131, Clamari, France.

The purpose of this study was to analyze the expression of B8.7 antigen and its implication in the low molecular weight B-Cell growth factor (LMW BCGF) proliferative pathway at the early stages of the human B-cell differentiation. After an overnight incubation in culture medium of B-cell precursor acute lymphoblastic leukemias (ALL), we demonstrated the presence of B8.7 antigen in 18 of 25 cases (72%). Such an incubation also induced a significant increase in the LMW BCGF responsiveness of ALL cells (P less than 0.03). In addition, we showed a significant correlation between B8.7 expression and the ability of pre-B ALL cells to respond to LMW BCGF. As previously described for normal B cells, the anti-B8.7 monoclonal antibody inhibited the LMW BCGF-dependent proliferation of pre-B ALL cells in a dose-dependent manner. These data indicate that B8.7 antigen is expressed and may be functionally related to the LMW BCGF pathway at the pre-B cell stages of differentiation. These results also suggest that human B-cell precursor ALL are not only phenotypically similar to their normal B lymphocyte counterparts, but are also sensitive to the same immunoregulatory cytokines that control normal cell growth.

UI MeSH Term Description Entries
D008222 Lymphokines Soluble protein factors generated by activated lymphocytes that affect other cells, primarily those involved in cellular immunity. Lymphocyte Mediators,Mediators, Lymphocyte
D008233 Lymphotoxin-alpha A tumor necrosis factor family member that is released by activated LYMPHOCYTES. Soluble lymphotoxin is specific for TUMOR NECROSIS FACTOR RECEPTOR TYPE I; TUMOR NECROSIS FACTOR RECEPTOR TYPE II; and TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 14. Lymphotoxin-alpha can form a membrane-bound heterodimer with LYMPHOTOXIN-BETA that has specificity for the LYMPHOTOXIN BETA RECEPTOR. TNF Superfamily, Member 1,TNF-beta,Tumor Necrosis Factor Ligand Superfamily Member 1,Tumor Necrosis Factor-beta,Lymphotoxin,Lymphotoxin-alpha3,Soluble Lymphotoxin-alpha,alpha-Lymphotoxin,Lymphotoxin alpha,Lymphotoxin alpha3,Lymphotoxin-alpha, Soluble,Soluble Lymphotoxin alpha,Tumor Necrosis Factor beta,alpha Lymphotoxin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011961 Receptors, Fc Molecules found on the surface of some, but not all, B-lymphocytes, T-lymphocytes, and macrophages, which recognize and combine with the Fc (crystallizable) portion of immunoglobulin molecules. Fc Receptors,Fc Receptor,Receptor, Fc
D002471 Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill. Neoplastic Transformation, Cell,Neoplastic Cell Transformation,Transformation, Neoplastic Cell,Tumorigenic Transformation,Cell Neoplastic Transformation,Cell Neoplastic Transformations,Cell Transformations, Neoplastic,Neoplastic Cell Transformations,Neoplastic Transformations, Cell,Transformation, Cell Neoplastic,Transformation, Tumorigenic,Transformations, Cell Neoplastic,Transformations, Neoplastic Cell,Transformations, Tumorigenic,Tumorigenic Transformations
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

C Leprince, and N Blumenfeld, and G Flandrin, and P Galanaud, and F Sigaux, and Y Richard
February 1990, Blood,
C Leprince, and N Blumenfeld, and G Flandrin, and P Galanaud, and F Sigaux, and Y Richard
July 1992, European journal of immunology,
C Leprince, and N Blumenfeld, and G Flandrin, and P Galanaud, and F Sigaux, and Y Richard
July 1987, Blood,
C Leprince, and N Blumenfeld, and G Flandrin, and P Galanaud, and F Sigaux, and Y Richard
November 1989, The Journal of clinical investigation,
C Leprince, and N Blumenfeld, and G Flandrin, and P Galanaud, and F Sigaux, and Y Richard
January 1989, Acta haematologica,
C Leprince, and N Blumenfeld, and G Flandrin, and P Galanaud, and F Sigaux, and Y Richard
January 1988, Journal of immunology (Baltimore, Md. : 1950),
C Leprince, and N Blumenfeld, and G Flandrin, and P Galanaud, and F Sigaux, and Y Richard
January 2013, International journal of hematology,
C Leprince, and N Blumenfeld, and G Flandrin, and P Galanaud, and F Sigaux, and Y Richard
August 2017, Cellular and molecular biology (Noisy-le-Grand, France),
C Leprince, and N Blumenfeld, and G Flandrin, and P Galanaud, and F Sigaux, and Y Richard
January 2020, Haematologica,
C Leprince, and N Blumenfeld, and G Flandrin, and P Galanaud, and F Sigaux, and Y Richard
August 1987, Cellular immunology,
Copied contents to your clipboard!